Vernakalant Hydrochloride

盐酸维那卡兰

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameVernakalant Hydrochloride
Drug Alias Name维那卡兰vernakalantum维纳卡兰维娜卡兰维钠卡兰 +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium channel alpha subunit blockersVoltage-gated potassium channel subunit Kv11.1 blockers
TargetsSodium channel alpha subunitVoltage-gated potassium channel subunit Kv11.1
Therapy Area/IndicationsAtrial FlutterAtrial Fibrillation
Global Approved IndicationsAtrial Fibrillation
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2010/09/01
Country/TerritoryCzechiaBelgiumBulgaria +[35] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesCorrevio Pharma
China Registration ClassN/A

Develop Information

Active CompaniesCorrevio PharmaMerck Sharp & Dohme BvUniversity Of Calgary +[8] 
Inactive CompaniesAstellas Pharma Us IncAdvanz Pharma CorpAstellas Pharma Inc
Active IndicationsAtrial Fibrillation
Inactive IndicationsAtrial Flutter

Other Information

ATC CodeC01BG11
Related LinksWikipediaDrugBankKEGG